Introduction
Electroconvulsive therapy (ECT) involves the induction of a generalized seizure with an electrical current. It was developed in 1938 and is widely used throughout the world in the treatment of severe depressive illness, mania, and schizophrenia. 1 It is estimated that approximately 100,000 patients in the USA per year are treated with ECT. 1 Treatments are typically administered twice or thrice weekly until clinical improvement occurs. An average course of therapy for an acute episode of illness is 6-10 treatments. Patients with highly medicationrefractory or recurrent illnesses often receive maintenance treatments at spaced intervals, typically once every 1-4 weeks, for extended periods of time to prevent relapse.
ECTwas developed, at least in part, on the theory that there is a biological antagonism between seizures and severe psychopathologic states such as psychosis. 2 While the intentional induction of seizures may on first blush appear to be a risk for inducing spontaneous seizures, several large-scale epidemiologic surveys find no evidence that ECT causes epilepsy. [3] [4] [5] In fact, much evidence indicates that ECT actually has anticonvulsant properties. 6 For example, in animal models, ECT (or electroconvulsive shock, as it is referred to in animals) has potent anti-kindling effects. 7 In humans, as a course of treatments progresses, the amount of electrical charge needed to induce seizures increases, and the length of seizures shortens, indicating anticonvulsant effects. 6 Finally, there is an intriguing literature indicating that in epileptic patients, ECT may reduce the frequency of spontaneous seizures, and in the pre-antiepileptic drug era, ECT was used in some circumstances for this very purpose. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Nonetheless, the occurrence of spontaneous epilepsy is not uncommon in the general population. Whereas it would be statistically highly unlikely for epilepsy to occur in a patient who only is receiving a 2-4 week course of ECT, maintenance courses of ECT can extend several years for chronically ill patients. Thus, a clinician treating a large number of maintenance ECT patients may expect an occasional one to develop epilepsy. Some of the challenges in such cases include determining whether ECT may have played a role in initiating the spontaneous seizures, how to control the epilepsy, and whether continued ECT can be administered safely and effectively. To our knowledge, there are no reports of such patients in the modern literature. There are numerous case reports of psychiatrically ill epileptic patients who receive ECTwithout apparent increase in spontaneous seizures. 10, [23] [24] [25] [26] At our facility, we treat approximately 300 patients per year with ECT. In reviewing our database over approximately the past decade, we found four patients receiving maintenance ECTwho developed definite or possible epilepsy. In three cases, continued ECT treatments were undertaken without complication. In one case, ECTwas discontinued. We describe these patients in detail and provide recommendations for clinical practice. Of note, all EEGs in this series were interpreted by Mayo Clinic neurologists with specialized training in epileptology.
Case reports Case 1
A 55-year-old divorced white female with a long history of recurrent bouts of depression and multiple medication and psychotherapy trials presented for her index hospitalization at our facility. She had received an uncomplicated, highly effective course of ECT treatments in her mid-40s without maintenance ECT. Medical history was negative for spontaneous seizures or risk factors thereof and positive for carpal tunnel syndrome, hysterectomy, and several non-specific chronic pain syndromes (headache, backache, and arthralgias). For the index hospitalization (at age 55), she received six ECT treatments with resolution of her depressive syndrome. She relapsed approximately 2 months later while taking citalopram and received another six treatments. She was discharged on mirtazapine and lithium. She again rapidly relapsed within a few weeks and ECT was commenced again, this time with the institution of maintenance ECT. Over approximately the next 32 months, she received 124 treatments. There was a break about midway through this course of about 4 months when she did not receive any treatments. Her depressive illness typically responded very well to index courses of thrice weekly treatments with fairly good maintenance of remission status during maintenance ECT; however, we were not able to stretch the inter-treatment interval to beyond once every 10-14 days. During this time, several high-dose, extended-duration psychotropic medication trials were attempted including mirtazapine (lithium was stopped upon resumption of ECT), bupropion, nefazodone, desipramine, escitalopram, tranylcypromine, and methylphenidate.
Approximately 1 month before the last ECT treatment, her sons noticed brief (about 2 min) spells of unresponsiveness, jerking movements, and occasional incontinence of urine. There were five witnessed episodes over a month's time. EEG revealed activation of bitemporal spikes with sleep. Head MRI was normal. There was no family history of epilepsy. Her neurologist, a specialist in epilepsy, diagnosed complex partial seizures and started her on carbamazepine. ECT was discontinued and duloxetine instituted for depression. Over follow up the next year and a half, there have been no other seizures. Depression severity has been waxing and waning but generally stable and there have been no psychiatric hospitalizations. Of note, from the time of first known complex partial seizure, there were approximately seven more ECT treatments before the diagnosis of epilepsy was made and ECTstopped. None of these latter treatments involved any complications.
Case 2
This patient was a 39-year-old single white male with a several-decade history of bouts of depression superimposed over chronic dysthymia. He had a remote history of alcohol abuse in remission for over a decade. Personal and family history was negative for seizures. Medical history was positive for mild bilateral hearing loss. He had been treated with several psychotropic medications over the years. He was referred for ECT in a major depressive episode. He responded well to index treatments and maintenance treatments were commenced. Over an approximately 7-month period, he received 39 ECT treatments. At that time, he revealed an approximately 2-month history of staring spells. His only psychotropic medication was mirtazapine. EEG revealed bilateral epileptiform activity while head MRI showed bilaterally symmetric increased T2 signal in the hippocampi with slight left posterior hippocampal atrophy. An epilepsy specialist diagnosed complex partial epilepsy and started him on carbamazepine. ECT was discontinued. There was good control of the seizures, but approximately 4 months later, severe depression returned and ECT was resumed. Over the next approximately year and a half, 40 treatments were administered and then stopped due to stable clinical status. His seizure disorder remained under good control. During the time on carbamazepine, there was never any trouble inducing seizures at ECT sessions. Psychotropic medications that were prescribed along with ECT during the period after epilepsy was diagnosed included, at various times, atomoxetine, trazodone, nefazodone, olanzapine, and modafanil.
Case 3
This patient was an 89-year-old widowed white female with an approximately 1-year history of dementia, with a more remote history of unspecified mood disorder. In the months after a myocardial infarction, her behavior degenerated into a severe state of delusionality and agitation. Past medical history, in addition to coronary artery disease, included hypertension, hypothyroidism, macular degeneration, esophagitis, and hiatal hernia. She had no personal or family history of epilepsy. At index psychiatric hospitalization at age 89, she received three ECT treatments with excellent psychopathologic resolution. She was discharged on citalopram but was readmitted a week later with fulminant relapse. Three more ECT treatments were again successful; citalopram was discontinued and maintenance ECT was commenced. Over approximately the next 2.5 years, she received a total of 69 ECT treatments at intervals usually of every other week to sustain clinical improvement. Her only psychotropic medication during the entire time was quetiapine.
Approximately halfway through this extended course of maintenance ECT, she was noted to have spells of shaking that lasted a few minutes. There did not seem to be loss of consciousness or incontinence. A neurologist specializing in epilepsy felt these to be of indeterminate etiology and ordered an EEG, which showed bitemporal but right dominant spikes and sharp waves that were felt to be potentially epileptogenic. Head computed tomography showed an old right parietal lobe infarct. She was started on depakote, which she received for the remaining 35 ECT treatments administered over the next approximately year and a half. Of note, the spells seemed to stop before the depakote was started. There was no trouble inducing seizures at ECTsessions in spite of depakote. ECT was eventually discontinued due to weakening physical status due to congestive heart failure, and she expired approximately 2 months after the last treatment.
Case 4
At index hospitalization at our facility, this was a 28-year-old married white female with a very extensive history of mood disorder and numerous psychiatric hospitalizations. She had been diagnosed with bipolar II disorder. She was given six ECT treatments for a depressive episode with apparent good results. She had no personal or family history of epilepsy and had no significant medical problems. Over the next approximately 2 years and 10 months, she received 86 ECT treatments for her highly recurrent, medication-refractory mood disorder. Most of her acute psychiatric presentations were for depression but occasionally for mixed depressive-hypomanic states. She was treated pharmacologically with quetiapine, carbamazepine (for manic prophylaxis), and bupropion for most of her ECT course.
During a hospitalization in which she received the last two of the 86 treatments, the diagnosis of possible epilepsy was made. This was based upon an episode of a spell, lasting approximately 30 s, which had occurred approximately 5-6 months earlier at home during which her husband noted her to be unresponsive to verbal cues and to appear to be choking. There were no tonic or clonic movements. At that time, the aspects of the spell were reported to her psychiatrist, who felt the differential diagnosis included a seizure, panic attack, or dissociative episode. She was already on carbamazapine, the dose of which was increased with a plan for watchful waiting. She had no further spells. However, during the hospitalization 5-6 months later, the decision was made to discontinue the carbamazapine due to loss of psychotropic efficacy. After 5 days off carbamazapine, an EEG was obtained which showed generalized atypical spike and wave bursts. Head MRI with and without gadolinium enhancement was normal. A neurology consultant recommended instituting lamotrigine. She had already had two ECT treatments in this hospitalization, and further ECT was held at that point. A few weeks later, after hospital discharge, she was noted to have another spell. Lamotrigine dose was increased. Four months later she was again hospitalized for depression, and two ECT treatments were administered without apparent complications. Three years after that, review of her medical chart reveals periodic hospitalizations for her mood disorder, numerous psychotropic trials, and no ongoing clinical evidence of spontaneous seizures.
Discussion
ECT is an indispensable treatment for some patients with highly recurrent, chronic, and psychotropic medication-refractory psychiatric illnesses. Extended courses of maintenance ECT may be necessary to sustain the benefits gained by an initial series of thrice-weekly treatments and may go on for many months or even years. As such, the risk of spontaneous epilepsy increases not necessarily as a result of the treatments per se but rather because new-onset epilepsy is not a terribly uncommon condition. It is our opinion that in this rare scenario, attempts should be made to discontinue ECT but that if needed, further treatments can probably be carried out practicably and safely.
When a patient receiving maintenance ECT develops epilepsy or, in the absence of definite clinical seizures, epileptogenic EEG activity, several issues need to be addressed by the psychiatric clinician. Presumably, some type of clinical events, or ''spells,'' have occurred which have lead to a neurological evaluation. The psychiatrist should communicate with the attending neurologist to coordinate the plan of care. A typical maintenance ECT patient is receiving the treatments at spaced intervals of 1-4 weeks, which should allow a thorough neurologic evaluation (e.g., office consultation, head imaging, and EEG) to be performed before the next scheduled treatment. One must consider whether ECT may have played an etiologic role in causing the epilepsy. In all likelihood, no definitive answer will be obtained. However, a conservative approach would be to stop further ECT. However, presumably the patient was receiving ongoing ECT because of a history of a highly recurrent, medication-refractory illness, so such a strategy may result in return of the psychopathology. Furthermore, if cessation of ECT is considered, then presumably a more aggressive psychopharmacologic approach would be considered which may have proconvulsant effects.
If review of the patient's psychiatric condition leads to the conclusion to continue ECT, the next question is, will ECT aggravate the new-onset seizure disorder? In all four of our patients, at least one ECT treatment was given after onset of the epilepsy (or abnormal EEG), and in two cases, extended ECT was given. None of the patients seemed to show any apparent spontaneous seizure activity during ECT after this time point. In fact, a likely more problematic issue for the ECT clinician is how to administer ECT effectively to a patient taking anti-epileptic medication, which presumably would make it more difficult to initiate seizures at ECT sessions. In the three of our patients who were taking anticonvulsant medication (carbamazepine in two cases and lamotrigine in one), further ECT seizures were easily obtained. However, ongoing communication between the treating psychiatrist and the neurologist is necessary should ECT seizures become impossible to achieve so that the lowest effective AED dose can be used and even a switch to another agent can be tried if needed.
There are some limitations to our case series. First, we cannot say whether ECT played an etiologic role in the development of epileptogenic activity. Indeed, many maintenance ECT patients have coexisting factors, such as neurological disorders, substance dependence, or concomitant psychotropic medications that may influence the development of epilepsy. At most, we can conclude that if epilepsy occurs during the course of maintenance ECT, the treatments can be continued safely. Second, the readings of the EEGs of course are subjective and open to interpretation by different clinical neurophysiologists. It is possible that some of the EEGs from our patient series would have been interpreted differently by other clinicians. Third, in the absence of video-EEG monitoring, we cannot rule out the possibility of pseudoseizures in some of our patients or even the possibility that some of the epileptiform activity on EEG may have pre-dated the ECT treatments. Still, we feel this series outlines the challenges the ECT clinician faces and does provide sound recommendations for clinical practice.
